IN8bio's INB-200 Phase 1 trial: all patients completing doses exceed 7-month PFS; one remains alive at 28.5+ months

IN8BIO, INC.

All ten patients who completed mandated doses exceeded progression-free survival (PFS) of 7 months, exceeding standard-of-care median PFS of 4-7 months.
One patient with IDH-mutant glioma remains alive and progression-free at 28.5+ months (median PFS for IDH-mutant patients in NEJM control arm: 11.1 months).
No treatment-related serious adverse events, dose-limiting toxicities, cytokine release syndrome, infusion reactions, or ICANS reported.
Three dosing cohorts: Cohort 1 (1 dose, 3 pts), Cohort 2 (3 doses, 4 pts), Cohort 3 (6 doses, 3 pts); additional enrollment in Cohort 3 expected to complete in 2023.
Preserved gamma-delta T cells found in relapsed tumor 148 days after initial DRI infusion, indicating durability of cells.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.